The Bill & Melinda Gates Foundation has launched a Grand Challenges Explorations topic “New Approaches for the Interrogation of Anti-malarial Compounds” with the goal of supporting unconventional and radically new approaches, methods, and assays to analyze, characterize and prioritize anti-malarial compounds and to glean more information required for the development of next generation malaria drugs. The Medicines for Malaria Venture (MMV) will make available to successful applicants the Malaria Box of 400 anti-malarial compounds, and for those projects that demonstrate a critical need to analyze a more extensive compound set, GlaxoSmithKline (GSK) will make available the 13,500 compounds that comprise the Tres Cantos Anti-Malarial Set (TCAMS). Applicants who would clearly benefit from additional expertise, access to tools, and/or capacity to achieve their research aims and objectives may propose that in Phase II of their GCE program they form a partnership with the GSK Tres Cantos Open Lab. Initial Phase I grants will be US $100,000 each, and projects showing promise will have the opportunity to receive Phase II funding of up to US $1 million.
A detailed description of this topic can be found at:www.grandchallenges.org/e_mal_op